IL1B and COVID-19: SARS-CoV-2 infection can induce a cytokine storm characterized by upregulation of IL-6 and IL-1, etc. [104,105,106,107], and this observation constitutes the rationale of anti-IL-6 and anti-IL-1 therapeutics in COVID-19 patients.